Amin Khan

Amin Khan leads efforts to use GreenLight’s platform to develop and launch vaccines. Amin joined GreenLight from GSK’s Vaccines business, where he was a member of the R&D leadership team. As head of GSK’s Technical R&D organization, he led Vaccines R&D Acceleration, where he was responsible for end-to-end accelerated development of the vaccine portfolio.

With 25 years of pharmaceutical and vaccines R&D experience, Khan’s recent work enabled the development and launch of Bexsero® & Shingrix® vaccines for meningitis B and shingles, respectively. He has also contributed to the development of mid-cycle vaccines at GSK (Vaccines for RSV, HSV, and CMV) and held accountability for scientific gating and prioritization of GSK’s vaccine discovery portfolio.

Khan is co-inventor for at least 16 patents and recently co-edited “Quality by Design—An Indispensable Approach to Accelerate Biopharmaceutical Product Development.” Amin holds a Ph.D. in pharmaceutical sciences from the University of Nottingham.